Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient ...

Eli Lilly has set the health and finance worlds abuzz with its new weight-loss pill, orforglipron. The company reported impressive trial outcomes, showing the drug outperformed Ozempic—a leading ...

Shares of Eli Lilly (LLY ... No hepatic safety signal was observed. Lilly expects to submit orforglipron for weight management to global regulatory agencies by the end of this year, with the ...

Eli Lilly stock might still have a lot of upside to it, despite increasing competition among weight-loss drugs. Rival Novo ...

Eli Lilly said that it planned to seek regulatory approval to market the drug for weight loss later this year, and early next year for diabetes. The F.DA. could take months and possibly longer to ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.

For the first time, scientists have pitted the two most popular weight loss drugs against each other in a direct competition ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...